Life Sciences Archive » April, 2018

Life Sciences - April, 2018

300 articles

• Insurers Seek To Nix Antitrust Suit Over Allergy Testing
• Berkeley Defends Bid To Overrule PTAB In CRISPR Row
• Vaccine Co. Pulls Suit Over Clinical Trial Into Fed. Court
• Jury Convicts Mass. Doc Of Giving Patient Info To Drug Co.
• Pfizer, Insurer Duel Over Venue For $30M Coverage Fight
• Hidden Expert-Pay Ruling Won't Improve J&J Odds At Retrial
• Migraine Patent Case Doomed By 10-Year Delay, Judge Rules
• Lawyer's Loose Lips Get Zimmer New Trial On $9M Damages
• Cooley Reps SteadyMed In $216M Sale To United Therapeutic
• Fed. Circ. Says Bid To Revisit VA Contract Ruling Too Late
• 3 Fla. Bellwether Cases Settled In Abilify MDL
• Don't Sleep On The Dormant Commerce Clause
• The Fastest Federal Civil Court For A Decade
• Ex-NECC Employees Don't Want Jury To Hear Of Drug Harms
• J&J Urges Court To Toss $117M Verdicts In NJ Talc Case
• Biogen Must Face FCA Suit Minus 17 State-Level Claims
• FTC Says Impax Must Sell 10 Generics After Amneal Deal
• Justices Seem Wary Of Strict Int'l Deference Standard
• 6 Firms Will Steer IPOs Totaling About $693M To Start May
• SEC Can Monitor Mass. Medical Co. Amid Fraud Charges
• DePuy Wins Infringement Damages Cap For Missing IP Marks
• A More Mobility-Friendly Approach To Noncompetes In Ill.?
• Bayer, J&J Beat Claims In Latest Philly Xarelto Trial
• Intuitive Says Doc's Deal Undercuts $2M Robot Fraud Claim
• Divided 7th Circ. Revives Atty's Age Discrimination Suit
• Merck Hit With Antitrust Suit Over Vaccine Bundle Discounts
• Serono Fights Biogen's Retrial Bid Over Nixed MS Drug Patent
• Atty Cites 1st Circ. In Seeking Contempt In Biolitec IP Case
• Attys Want $1.2M Fees From Forest Labs Gender Bias Deal
• Teva Settles Case Over Alleged Info Sharing With Rival CEO
• Israeli Med Device Developer Closes $70M Series C Round
• Ranbaxy Takes Patent Arbitration Fight To Texas Justices
• Pleading A Personal Jurisdiction Defense Late In The Game
• Hidden Expert Pay Gets J&J New Trial After $502M Verdict
• Transfer Of Lipozene Class Action Stands, 9th Circ. Says
• Texas Lab Wants Judge To Rethink $30.6M FCA Judgment
• Deals Rumor Mill: Eli Lilly, TransUnion, Quality Care
• Pfizer Slams Out-Of-State Claims Over Robitussin Label
• Fed. Circ. Says Merck Atty's Lies Doomed $200M Patent Win
• GSK, Zofran Users Bicker Over Scope Of Patient Discovery
• Dems Concerned House Opioid Bills Too Rushed
• Counterfeit Cosmetics: Fake Beauty, Real Danger
• Bristol-Myers Squibb: A Dangerous Sword
• Illumina DNA Patent Previously Found Valid, PTAB Says
• FDA Warning Wire: Spring Storm Over Youth E-Cig Sales
• Genentech Asks Fed. Circ. To Affirm Nix Of Inducement Claims
• Hong Kong OKs Listing Reforms To Allow Dual-Class Stock
• LabCorp Hit With Antitrust Suit Over Del. Medicaid Services
• Justices Ask What Deference US Courts Owe Foreign Gov'ts
• Deals Rumor Mill: Takeda, HNA Group, Didi
• Eyedrops Ruling Invites 'Abusive' Suits, High Court Hears
• Valeant Can Add NY Investor Fraud Suit To 27 Others In NJ
• Biotech Co. Execs Charged In $12.7M Painkiller Fraud
• Takeda Inches Closer To Shire Buy With £46B Offer
• Bard Seeks New Trial Over Vein Filters After $3.6M Verdict
• Antitrust Damages Analysis Can Respect International Comity
• Aspire Universal Unveils $300M Precision Medicine Fund
• Ballard Can't Arbitrate IP Malpractice Suit, Judge Told
• AbbVie Disputes $3M AndroGel Verdict In MDL Bellwether
• Arthrex Denied 2nd Shot At Estoppel Challenge By Fed. Circ.
• Akorn Sues Fresenius Over Nixed $4.3B Merger
• EU, Mexico Agree To Broader Trade Deal Nixing Tariffs
• Construction Firm Leads 4 IPO Launches Totaling $468M
• 3 Sentenced In $16.6M Fraudulent Medical Device Scheme
• Docufilm Maker Denied Access To Theranos Depo Videos
• Accutane Testimony Wasn't Reliable, NJ Justices Told
• Genetics Co. Hid Cancer Test Overbilling, Investor Says
• Allergan To Pay $500K To End Calif. Faulty Lap-Band Claims
• How States, Federal Agencies Are Challenging Drug Prices
• Medical Device Cybersecurity: Preparing For The Worst
• Investors, Pernix Set $75M Stalking Horse Bid For Orexigen
• FDA's Essure Order Affirms Role Of Learned Intermediary
• Cephalon's $125M Antitrust Deal Is Valid, Atty Power Unknown
• Alnylam, Dicerna Settle Trade Secrets Case Ahead Of Trial
• Vitamin C Importers Urge Less Int'l Deference At High Court
• Janssen Escapes Whistleblower Suit Over Off-Label Opioids
• 6 Firms To Guide Tech-Heavy IPO Lineup Set To Exceed $1.3B
• Shire Weighing Revised £44B Buyout Offer From Takeda
• Disney Workers Urge 9th Circ. To Revive Valeant ERISA Suit
• Oregon Tribe Sues Pharma Cos. Over Opioid Epidemic
• Bayer, J&J Can't Nix Xarelto Case Midtrial, Patient Says
• Experts Look To Congress To Stem Patent-Eligibility 'Chaos'
• MiraLAX Generics Get FDA Reprieve Despite Bayer Objections
• Health Hires: Goodwin, Shook Hardy, Michael Best, Orrick
• Ex-Aveo CFO Denied Quick Win In SEC's Cancer Drug Suit
• Taxation With Representation: Freshfields, Thompson, Davis
• Fed. Circ. Revives Medinol Patent Suit Killed By Laches
• Tax Critic Laments Federal Code's Effect On Marijuana Market
• Will High Court Ever End Circuit Split Over FCA Pleading?
• Biogen Pays Pharma Co. Ionis $1B To Extend Partnership
• FDA Offers Guidance On Making Opioid Addiction Treatments
• Pa. Court Won't Derail State's Medical Marijuana Program
• Rule 23 Changes: Avoid Delays In Class Settlement Approval
• CytRx, Class Dispute $685K Pump & Dump Deal Fee Award
• Judge Unseals $2 Million Fee Request In Adderall Patent Suit
• Bio-Pharm Must Face Generic-Drug Supply Contract Suit
• 3 IPOs Tap Markets For $841M With Mixed Results
• Amneal Says Fed. Circ. Redo In Drug Patent Row Unnecessary
• Allergan, Tribe Fight PTAB's Immunity Denial At Fed. Circ.
• 5 Takeaways As DEA Mulls Slashing Opioid Output
• Bayer, J&J Urge Judge To Ax Philly Xarelto Case Midtrial
• Abbott Must Give Docs To Alere Investors In Stock-Drop Suit
• Pfizer Gets Final Nod On $94M Celebrex Antitrust Settlement
• Boehringer Ducks TCPA Suit Over Faxed Seminar Invites
• Jones Day Guides P&G's €3.4B Buy Of Merck Health Brands
• The Flawed European Remedy To Bayer-Monsanto Deal
• Shire Spurns £44B Takeover Offer From Takeda
• Hundreds Seek To Centralize NJ Taxotere Hair Loss Suits
• Fed. Circ. Affirms PTAB Ax Of Cialis, Adcirca Patents
• Ex-Pharma Staffing Exec Gets Noncompete Suit Tossed
• Deals Rumor Mill: Altice, Carl Icahn, Grail
• Pharmacy, PE Fund Owner Want Tricare FCA Suit Trashed
• Best Practices For Building A Better Meeting
• Momenta, Sandoz Ask To Appeal Antitrust Claims Mid-Suit
• Eye Drop Suit Must Stay Tossed, Pharma Cos. Tell 1st Circ.
• UK Patent Ruling Sharpens Contrast With US Practice
• Missouri Talc Decision Could Signal Mass Tort Sea Change
• DEA Proposes Capping Opioid Quotas
• W.Va. Reaches $550K Settlement With Shuttered Pill Mill
• Pfizer, Ranbaxy Look To Dump State Claims In Lipitor MDL
• Calif. Court Revives Avandia Injury Claims Against GSK
• FDA Warning Wire: Mosquitoes, Gnats And Fungus, Oh My
• 5 Ways Law Firms Are Becoming More Like Hotels
• Allergan To Pay $3.5M To Resolve Lap-Band FCA Allegations
• Advent In Talks To Buy Sanofi Euro Generics Arm For $2.3B
• Fed. Circ.'s Latest Guidance On Method-Of-Treatment Claims
• Dropping Ranks: Lathrop's Rough Patch
• Dropping Ranks: Andrews Kurth's Pre-Merger Dip
• Why BigLaw's Partnerships Are Shrinking
• Dropping Ranks: Stroock's 'Shrink To Grow' Strategy
• Miami Launches Suit Against Drug Cos. Over Opioid Abuse
• NJ High Court Urged To Consolidate J&J Hernia Mesh Suits
• Confidentially Marketed Public Offerings Carve Bigger Niche
• Highlights Of ABA Antitrust Spring Meeting: Part 1
• Fed. Circ. Affirms IP Win For Sunovion On Generic Latuda
• Jones Day Grabs Ex-Freshfields Litigator, Arbitration Pro
• PTAB Denies 2 More Challenges To Maquet Blood Pump IP
• Gorsuch's 1st Year Shows He Is A Conservative Activist
• J&J Won't Get High Court Look At FCA 'Particularity' Rule
• OvaScience Board Ducks Shareholders' IVF Treatment Suit
• Cooper-Vemedia Pays Sanofi $195M For 12 Pharma Brands
• Shire Inks $2.4B Sale Of Cancer Biz As Takeda Eyes Takeover
• Supreme Court Seeks Gov't View Of Gilead FCA Case
• How 5 Firms Grew Without Merging
• The Law360 400
• Law360 Reveals 400 Largest US Firms
• Megafirms Find New Heights In Grounded Market
• Vanda Schizophrenia Drug Patentable, Fed. Circ. Says
• Ex-Katten Atty Pushes To Deep-Six Fraud Verdict
• Canadian Drug Cos. To Pay $34M For Selling Phony Products
• SEC Charges Supplement Co. CEO With Penny Stock Fraud
• Big Dental Distributors Can't Brush Off Antitrust Suit
• 8 Firms To Steer IPOs Exceeding $2.6B As April Heats Up
• Chinese Gov't To Argue Before High Court In Vitamin C Case
• Aggrenox End-Payors Want $18M Atty Fees In $54M Deal
• 4th Circ. Finds Md. Drug Pricing Law Unconstitutional
• Pfizer Can't Shake Suit Over Deceptive Robitussin Labels
• Funds Fight Bids To Toss $80B Valeant Price-Gouging Suit
• A Chat With Baker Botts CMO Gillian Ward
• Deals Rumor Mill: PAG Asia, Mylan, SpaceX
• Bard Hit With $35M Punitive Damages In NJ Mesh Case
• Celgene Sues To Block Dr. Reddy's Revlimid Generic
• Sanofi's FCA Suit Docs Not All Privileged, Ex-Worker Says
• FDA Bans Bulk Sale Of Concentrated Caffeine Supplements
• Preempting Preemption: Device Cases After Shuker — Part 2
• NuVasive Urges 9th Circ. To Toss $27M Poaching Verdict
• Full Fed. Circ. Won't Take On Ariosa Re-Exam Challenge
• Sorin Denies Family's Claim It Hid Heart Valve Info From FDA
• Avee Objects To Abbott Dismissal Move In $36M Escrow Suit
• Fed. Circ. OKs PTAB's Trim Of Luitpold Iron Patents
• States Expanding Efforts To Tackle Prescription Drug Prices
• FDA Unveils Guidance On DNA Testing Technology
• Task Force Makes 11 Drug-Related Arrests On Tribal Lands
• J&J Unit Wants Whistleblower Docs In Hip Implant FCA Suit
• Unraveling FDA's Recent Flurry Of Tobacco Activity
• Texas Doctor Charged With Trading Xanax For Favors
• Drugmakers Duped Medicaid Rebate Regulators, 3rd Circ. Told
• FDA Proposes New Way To Approve Updated Medical Devices
• Fenwick To Move NYC Office To Tech Hub Flatiron District
• Bard Hit With $33M Pelvic Mesh Verdict In NJ
• What Cos. Need To Know About China's New Market Regulator
• Fed. Circ. Case May Change Biosimilar IPR Strategy
• Preempting Preemption: Device Cases After Shuker — Part 1
• Finance-Savvy Millennials Are Shifting Business Of Law
• Orexigen Reaches Deal With Creditors On $70M DIP Loan
• Opioid MDL Judge Sets Litigation Plan, Bashes DEA
• Bard Hustled Defective Meshes To Market, Jury Told In Closing
• FTC Appeals Big Loss To A Shire Unit In Sham Petition Case
• Ropes & Gray Advises Alexion's $855M Swedish Drug Co. Buy
• Navajo Nation Is Latest To Sue Pharma Cos. Over Opioids
• PTAB Rightfully Rejected Merck Patent App, Fed. Circ. Says
• USPTO Head Calls For New Path To Restore Patent Stability
• Lewis Brisbois Nabs Product Liability Atty For Philly Office
• Farmers Win OK Of $1.5B Syngenta GMO Corn Settlement
• Theranos, Walgreens Dodge Some Claims In Blood Test Row
• Teva Investor Suit Over $40.5B Merger Sent To Conn.
• EU OKs Bayer's Divestiture To BASF In $62B Monsanto Deal
• J&J Hit With $80M Punitive Damages Verdict In NJ Talc Case
• Attorney-Client Privilege Is Alive And Well
• Dissolving Practice
• J&J Fights Bid For Punitive Damages In Asbestos Talc Case
• Shkreli Must Repay Investor $388K Over Property Deal Woes
• Orexigen Noteholders Say $70M DIP Loan Strips Value
• Device Cos., Hospital Sue 18 Cos. Over Anti-Aging Microneedles
• Deals Rumor Mill: Sprint, L'Oreal, Sinochem
• Drugmakers Assail FDA For Nixing Generic Laxative Approval
• Par Pharma Blasts $102M Bond Ask In Trade Secrets Suit
• FDA Warning Wire: Dead Raccoon, Too-Strong Cough Syrup
• Littler Brings 2 Former Shareholders Back To Chicago
• PTAB To Review Hair Loss Treatment Patent After Rehearing
• Dissolving Practice: How To Fix A Dysfunctional Law Firm
• 5 Attys Tapped For Pharmacy Negotiating Team In Opioid MDL
• Pro Tennis Orgs Hit With Player's $10M Blood Draw Injury Suit
• Ballard Spahr Wants IP Rental Malpractice Claims Arbitrated
• Deals Rumor Mill: Bayer, Viacom, Haidilao
• Illumina Urges Court To Uphold Jury Verdict Against Ariosa
• FDA Slaps 'Unique' Limit On Bayer's Essure Sales
• White House Asked To Produce Info On Opioid Crisis Work
• Cancer-Focused Biopharma Co. Snags $100M From Investors
• Dissolving Practice: Partner Agreement Clauses That Can Help
• Amgen's Patent Not Used In Neulasta Biosimilar, Mylan Says
• Novartis Buys Gene Therapy Co. Avexis In $8.7B Deal
• The Time Is Right For New Jersey To Adopt Daubert
• Medical Device Cos. Deny FCA Suit's Excess Blood-Test Claim
• Mylan Can Sell Generic Of Shire's Lialda, Fed. Circ. Confirms
• Cogentix Hit With Stockholder Class Challenge To $239M Sale
• 2 Firms To Guide IPOs Totaling $170M Led By Tech Startup
• 9th Circ. Reinvigorates Sex Aid Supplement Suit
• Bayer, J&J Botched Xarelto Bleeding Warning, Pa. Jury Told
• Calif. County Can't Escape Hemp Seizure Suit, Court Told
• Health Hires: Dentons, Greenberg Traurig, Morgan Lewis
• Ariad Investors' Attys Seek 30% Of $3.5M Class Settlement
• Dissolving Practice: The Unfinished Business Doctrine
• Drug Cos., Pharmacies Want Pause In Cherokee Opioid Suit
• Congress' Fix To Tribal Sovereign Immunity Misses The Point
• China Not Backing Down After Latest US Tariff Threat
• Trans-Pacific Partnership Lost Important IP Provisions
• What To Do After A Product Recall
• Maine Lab Will Arbitrate Mice Row With University
• Hong Kong Aims To Grab Bigger Share Of Global Listings
• Bard Meshes Didn't Harm Woman, Harvard Doctor Tells Jury
• Otsuka, Bristol Seek Quick Win On Abilify Fail-To-Warn Claims
• Impax's $20M Settlement In Pay-For-Delay Suit Clears Hurdle
• Trump Floats New Tariffs As US-China IP Scrap Intensifies
• Aussie DNA Test Co. Keeps Win In Patent Row With Texas Dr.
• China Tells Justices It Faced Hostility In Vitamin C Case
• Ill. Pharmacist Gets 4 Years For $2.4M Insurance Fraud
• Nonprofits Urge HHS To Take Over Sarepta's Exondys Patents
• Ex-NHL Owner Conned Investors Out Of $14M, SEC Says
• AbbVie Inks Humira IP Licensing Deal With Samsung Bioepis
• Sandoz Rehashed Arguments In Rituxan IP Challenge: PTAB
• Aetna HIV Privacy Suit Goes Back To Calif. State Court
• 1st Circ. Upholds Sarepta Win In Drug Trial Investor Suit
• CardioNet's Heart Monitor Patents Get Trimmed Under Alice
• MusclePharm Sues Liberty Again Over SEC Case Costs
• 3rd Circ. Affirms Merck Win In Shingles Vaccine Case
• PetIQ's Deal To Buy Veterinary Clinic Chain Faces Challenge
• J&J Hit With $37M Asbestos Talc Verdict In NJ
• J&J Case Raises Estoppel Issue For Successful IPR Litigants
• Applying The Business Judgment Rule To Director Pay Claims
• What To Do During A Product Recall
• J&J Loses Mistrial Bid Over Claims At Asbestos Talc Trial
• McKesson Hit With FCA Suit Alleging Misbranded Drugs
• Chinese Scientist Gets 10 Years For Plot To Steal GMO Seeds
• Judge Tosses Teva Investors' Price-Fixing Suit From Bench
• Supplement Co. Manager Cops To Selling Illegal Stimulants
• FDA Head Puts Spotlight On Internet's Role In Opioid Crisis
• Okla. Tribe Says Drug Cos. Played Major Role In Opioid Abuse
• Fla. Medical Pot Provider Challenges Dispensary Limits
• Brookfield-Backed GrafTech Launches $850M IPO
• Prescribing Doc's Testimony Key In 2nd Philly Xarelto Trial
• 3 New Settlements Highlight DOJ Scrutiny Of Device Makers
• Tribe Says Cannabis Co.'s $10M Suit Based On Void Contract
• 'Malpractice' By A Computerized Decision-Support Tool?
• Bard Can't Get Surgery Kit Patent Suit Out Of Illinois
• From Rocket Launchers To Soybeans: US, China At The Brink
• VC Firm Sofinnova Raises €275M For Life Science Investments
• What To Do Before A Product Recall
• Lawmaker, IP Orgs Contest On-Sale Bar Ruling At High Court
• Deals Rumor Mill: CBS, Pfizer, Mediaset
• J&J Tests Weren't Meant To Find Asbestos In Talc, Jury Told
• Vitamin Shoppe Answer Claims It Pumped Up Powder Benefits
• AbbVie Says Suit Over Nixed $54B Shire Merger Should End
• USTR Targeting Chinese Goods In Clash Over IP Rules
• Texas Lab Must Pay $30.6M For Inflated Mileage Charges
• Another Cops To Bribery Over NJ Medical Device Contract
• Fed. Circ. Clears PTAB's Trim Of EMED Needle Shield Patent
• Latham Adds Wilson Sonsini Corporate Partner In Calif.
• King & Spalding Nabs Cooley IP Trial Partner
• Rival Hits MiMedx With $6.8M Breach, Trade Secrets Suit
• DOJ Looks To Help Resolve Opioid MDL As Friend Of Court
• Innovator Liability Is The Least Scary Thing About Rafferty
• NN Scoops Up PE-Backed Medical Device Co. In $375M Deal
• J&J Says At Trial's Close Its Talc Tested Free Of Asbestos
• Merck Says Holding Co. Must Arbitrate Pay-For-Delay Claims
• No Fees For Roche Or Nova After Failed IP, Breach Row
• Kimberly-Clark, Halyard Get $450M Punitives Slashed
• Global Health Care Compliance: Spotlight On Korea
• Biotech Startup Seres Beats Suit Over Stock Drop
• Innovator Liability: A Pandora's Box For Pharma Cos.?